MMP2 and hepatocellular carcinoma: Remarkably, bortezomib alone did not improve migratory ability, probably because no further enhancement of the migration-promoting effect occurs above a certain MMP-2 level in our cellular HCC models (Figure 8g,h: compare NTC with/without bortezomib treatment).